1269.5000 -16.90 (-1.31%)
NSE Jan 09, 2026 15:31 PM
Volume: 38,962
 

1269.50
-1.31%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. is trading above its 200 day SMA of 1077.5
More from Tatva Chintan Pharma Chem Ltd.
Recommended